Immunomedics (Immunomedics) EBIT : $-306.02 Mil (TTM As of Jun. 2020)

View and export this data going back to 1990. Start your Free Trial

What is Immunomedics EBIT?

Immunomedics's earnings before interest and taxes (EBIT) for the three months ended in Jun. 2020 was $-52.27 Mil. Its earnings before interest and taxes (EBIT) for the trailing twelve months (TTM) ended in Jun. 2020 was $-306.02 Mil.

EBIT or Operating Income is linked to Return on Capital for both regular definition and Joel Greenblatt's definition. Immunomedics's annualized ROC % for the quarter that ended in Jun. 2020 was -445.14%. Immunomedics's annualized ROC (Joel Greenblatt) % for the quarter that ended in Jun. 2020 was -566.88%.

EBIT is also linked to Joel Greenblatt's definition of earnings yield. Immunomedics's Earnings Yield (Joel Greenblatt) % for the quarter that ended in Jun. 2020 was -1.56%.

Immunomedics EBIT Historical Data

The historical data trend for Immunomedics's EBIT can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Immunomedics EBIT Chart

Immunomedics Annual Data

Trend

Jun10

Jun11

Jun12

Jun13

Jun14

Jun15

Jun16

Jun17

Jun18

Dec19

EBIT

Get a 7-Day Free Trial

-45.98

-58.71

-147.77

-250.48

-316.98

Immunomedics Quarterly Data
	Sep15	Dec15	Mar16	Jun16	Sep16	Dec16	Mar17	Jun17	Sep17	Dec17	Mar18	Jun18	Sep18	Dec18	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20
EBIT	Get a 7-Day Free Trial															-65.33	-84.58	-89.63	-79.54	-52.27

Competitive Comparison of Immunomedics's EBIT

For the Biotechnology subindustry, Immunomedics's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Immunomedics's EV-to-EBIT Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Immunomedics's EV-to-EBIT distribution charts can be found below:

* The bar in red indicates where Immunomedics's EV-to-EBIT falls into.

Immunomedics EBIT Calculation

EBIT, sometimes also called Earnings Before Interest and Taxes, is a measure of a firm's profit that includes all expenses except interest and income tax expenses. It is the difference between operating revenues and operating expenses. When a firm does not have non-operating income, then Operating Income is sometimes used as a synonym for EBIT and operating profit.

EBIT for the trailing twelve months (TTM) ended in Jun. 2020 adds up the quarterly data reported by the company within the most recent 12 months, which was $-306.02 Mil.

Immunomedics (NAS:IMMU) EBIT Explanation

1. EBIT or Operating Income is linked to Return on Capital for both regular definition and Joel Greenblatt's definition.

Immunomedics's annualized ROC % for the quarter that ended in Jun. 2020 is calculated as:

	ROC % (Q: Jun. 2020 )
=	NOPAT	/	Average Invested Capital
=	Operating Income * ( 1 - Tax Rate % )	/	( (Invested Capital (Q: Mar. 2020 )	+	Invested Capital (Q: Jun. 2020 ))	/ count )
=	-212.048 * ( 1 - 0% )	/	( (40.22	+	55.053)	/ 2 )
=	-212.048	/	47.6365
=	-445.14 %

where

	Invested Capital		(Q: Mar. 2020 )
=	Total Assets	-	Accounts Payable & Accrued Expense	-	Excess Cash
=	Total Assets	-	Accounts Payable & Accrued Expense	-	( Cash, Cash Equivalents, Marketable Securities	-	max(0, Total Current Liabilities	-	Total Current Assets	+	Cash, Cash Equivalents, Marketable Securities	))
=	594.106	-	59.268	-	( 540.62	-	max(0, 67.105	-	561.723	+	540.62	))
=	40.22

	Invested Capital		(Q: Jun. 2020 )
=	Total Assets	-	Accounts Payable & Accrued Expense	-	Excess Cash
=	Total Assets	-	Accounts Payable & Accrued Expense	-	( Cash, Cash Equivalents, Marketable Securities	-	max(0, Total Current Liabilities	-	Total Current Assets	+	Cash, Cash Equivalents, Marketable Securities	))
=	1077.13	-	59.862	-	( 975.518	-	max(0, 81.261	-	1043.476	+	975.518	))
=	55.053

Note: The Operating Income data used here is four times the quarterly (Jun. 2020) data.

2. Joel Greenblatt's definition of Return on Capital:

Immunomedics's annualized ROC (Joel Greenblatt) % for the quarter that ended in Jun. 2020 is calculated as:

	ROC (Joel Greenblatt) %		(Q: Jun. 2020 )
=	EBIT	/	Average of (Net fixed Assets	+	Net Working Capital)
=	EBIT	/	Average of (Property, Plant and Equipment	+	Net Working Capital)
			Q: Mar. 2020		Q: Jun. 2020
=	EBIT	/	( ( (Property, Plant and Equipment + Net Working Capital)	+	(Property, Plant and Equipment + Net Working Capital) )	/	count )
=	-209.06	/	( ( (32.15 + max(-38.165, 0))	+	(33.512 + max(8.096, 0)) )	/	2 )
=	-209.06	/	( ( 32.15	+	41.608 )	/	2 )
=	-209.06	/	36.879
=	-566.88 %

where Working Capital is:

	Working Capital		(Q: Mar. 2020 )
=	(Accounts Receivable	+	Total Inventories	+	Other Current Assets)	-	(Accounts Payable & Accrued Expense	+	Defer. Rev.	+	Other Current Liabilities)
=	(0	+	0	+	21.103)	-	(59.268	+	0	+	0)
=	-38.165

	Working Capital		(Q: Jun. 2020 )
=	(Accounts Receivable	+	Total Inventories	+	Other Current Assets)	-	(Accounts Payable & Accrued Expense	+	Defer. Rev.	+	Other Current Liabilities)
=	(22.258	+	20.807	+	24.893)	-	(59.862	+	0	+	0)
=	8.096

When net working capital is negative, 0 is used.

Note: The EBIT data used here is four times the quarterly (Jun. 2020) EBIT data.

3. It is also linked to Joel Greenblatt's definition of Earnings Yield:

Immunomedics's Earnings Yield (Joel Greenblatt) % for today is calculated as:

Earnings Yield (Joel Greenblatt) %	=	EBIT (TTM)	/	Enterprise Value (Q: Jun. 2020 )
	=	-306.015	/	19631.649
	=	-1.56 %

Immunomedics EBIT Related Terms

Thank you for viewing the detailed overview of Immunomedics's EBIT provided by GuruFocus.com. Please click on the following links to see related term pages.

Immunomedics (Immunomedics) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Immunomedics Inc (NAS:IMMU) » Definitions » EBIT

Comparable Companies

Traded in Other Exchanges

N/A

Address

300 The American Road, Morris Plains, NJ, USA, 07950

Website

http://www.immunomedics.com

Immunomedics Inc is a clinical-stage biopharmaceutical company, based in the United States. The company develops monoclonal antibody-based products for the targeted treatment of cancer and autoimmune disorders, among others. Its portfolio of products under investigation include antibody-drug conjugates that target the tumor-reducing toxic effects of chemotherapeutic treatments. The company's pipeline includes products targeting solid tumors and hematologic malignancies, among other diseases in clinical and preclinical development. The company is marketing specific diagnostic imaging agents to detect bone infections in Europe, Canada, and Australia. The company has subsidiaries in the Netherlands and Germany to manage sales and clinical trials in Europe.

Executives

Scott A Canute	director	FLEXION THERAPEUTICS, INC., 10 MALL ROAD, SUITE 301, BURLINGTON MA 01803
Barbara Gayle Duncan	director	C/O INTERCEPT PHARMACEUTICALS, INC., 18 DESBROSSES STREET, NEW YORK NY 10013
Peter Barton Hutt	director
Charles M Baum	director	C/O MIRATI THERAPEUTICS INC., 9393 TOWNE CENTRE DRIVE, STE 200, SAN DIEGO CA 92121
Khalid Islam	director	C/O IMMUNOMEDICS, INC., 300 THE AMERICAN ROAD, MORRIS PLAINS NJ 07950
Venbio Select Advisor Llc	director, 10 percent owner, other: See Remarks	110 GREENE STREET, SUITE 800, NEW YORK NY 10012
Behzad Aghazadeh	director, 10 percent owner, other: See Remarks	C/O AVORO CAPITAL ADVISORS LLC, 110 GREENE STREET, SUITE 800, NEW YORK NY 10012
Robert Azelby	director	307 WESTLAKE AVE. NORTH, STE 300, SEATTLE WA 98109
Harout Semerjian	director, officer: President and CEO	300 THE AMERICAN ROAD, C/O IMMUNOMEDICS, INC., MORRIS PLAINS NJ 07950
Kurt J. Andrews	officer: Chief Human Resources Officer	C/O AMICUS THERAPEUTICS, INC., 1 CEDAR BROOK DRIVE, CRANBURY NJ 08512
Bryan Ball	officer: Chief Quality Officer	300 THE AMERICAN ROAD, MORRIS PLAINS NJ 07950
Jared Freedberg	officer: General Counsel	300 THE AMERICAN ROAD, MORRIS PLAINS NJ 07950
Usama Malik	officer: Chief Business Officer & CFO	300 THE AMERICAN WAY MORRIS PLAINS NJ 07950
Brendan Delaney	officer: Chief Commerical Officer	300 THE AMERICAN WAY, MORRIS PLAINS NJ 07950
Lorettta M Itri	officer: Chief Medical Officer